Citations

Mayo Clinic

Showing 10 of 108523 citations.

Coordinated Targeting of S6K1/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma
Behrmann, Catherine A. , Ennis, Kelli N. , Sarma, P.N. , Wetzel, Collin , Clark, Nicholas A. , Handorf, Kate M. Von , Vallabhapurapu, Subrahmanya , Andreani, Cristina , Reigle, James , Czyzyk-Krzeska, Maria , Kendler, Ady , Sengupta, Soma , Dasgupta, Biplab , Plas, David R. , Sarma, Pranjal , Von Handorf, Kate M , Scaglioni, Pier Paolo , Meller, Jarek , Czyzyk-Krzeska, Maria F , Kendler, Ady , Qi, Xiaoyang , Sarkaria, Jann N , Medvedovic, Mario , Sengupta, Soma , Dasgupta, Biplab , Plas, David R , Qi, Xiaoyang , Sarkaria, Jann N.

Cancer Research Communications | August 1, 2024 | Volume: 4 | Issue: 8 | Pages: 2215-2227

10.1158/2767-9764.crc-23-0631 | PMID 39087397 Get It

Abstract Intrinsic resistance to targeted therapeutics in PTEN-deficient glioblastoma (GBM) is mediated by redundant signaling networks that sustain critical metabolic functions. Here, we demonstrate that coordinated inhibition of the ribosomal protein S6 kinase 1 (S6K1) and the receptor tyrosine kinase AXL using LY-2584702 and BMS-777607 can overcome network redundancy to reduce GBM tumor growth. This combination of S6K1 and AXL inhibition suppressed glucose flux to pyrimidine biosynthesis. Genetic inactivation studies to map the signaling network indicated that both S6K1 and S6K2 transmit growth signals in PTEN-deficient GBM. Kinome-wide ATP binding analysis in inhibitor-treated cells revealed that LY-2584702 directly inhibited S6K1, and substrate phosphorylation studies showed that BMS-777607 inactivation of upstream AXL collaborated to reduce S6K2-mediated signal transduction. Thus, combination targeting of S6K1 and AXL provides a kinase-directed therapeutic approach that circumvents signal transduction redundancy to interrupt metabolic function and reduce growth of PTEN-deficient GBM. Significance: Therapy for glioblastoma would be advanced by incorporating molecularly targeted kinase-directed agents, similar to standard of care strategies in other tumor types. Here, we identify a kinase targeting approach to inhibit the metabolism and growth of glioblastoma.
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis
Wisniowski, Brendan , Geyer, Susan, Milani, Paolo , Veelken, Kaya, Kumar, Shaji , Liedtke, Michaela , Dooley, Katharine , Landau, Heather , Petrlik, Erica , Lentzsch, Suzanne , Coltoff, Alexander , Bladé, Joan , Cibeira, María Teresa , Cohen, Oliver C. , Foard, Darren, Gillmore, Jullian, Wechalekar, Ashutosh , Gertz, Morie A., Milani, Paolo , Gillmore, Julian D , Muchtar, Eli , Palladini, Giovanni , Merlini, Giampaolo , Schönland, Stefan , Hegenbart, Ute , Leung, Nelson , Dispenzieri, Angela , Kastritis, Efstathios , Dimopoulos, Meletios Α. , Ulloa, Patricia, Sanchorawala, Vaishali , Szalat, Raphaël , Cohen, Oliver , Gillmore, Julian D. , Lachmann, Helen J. , Wechalekar, Ashutosh D. , Gertz, Morie A.

JAMA Oncology | August 1, 2024 | Volume: 10 | Issue: 10 | Pages: 1362

10.1001/jamaoncol.2024.2629 | PMID 39088206 Get It

ImportanceKidney light chain (AL) amyloidosis is associated with a risk of progression to kidney replacement therapy (KRT) and death. Several studies have shown that a greater reduction in proteinuria following successful anticlonal therapy is associated with improved outcomes.ObjectiveTo validate graded kidney response criteria and their association with kidney and overall survival (OS).Design, Setting, and ParticipantsThis retrospective, multicenter cohort was conducted at 10 referral centers for amyloidosis from 2010 to 2015 and included patients with kidney AL amyloidosis that was evaluable for kidney response and who achieved at least hematologic partial response within 12 months of diagnosis. The median follow-up was 69 (54-88) months. Data analysis was conducted in 2023.ExposureFour kidney response categories based on the reduction in pretreatment 24-hour urine protein (24-hour UP) levels: complete response (kidCR, 24-hour UP ≤200 mg), very good partial response (kidVGPR, >60% reduction in 24-hour UP), partial response (kidPR, 31%-60% reduction), and no response (kidNR, ≤30% reduction). Kidney response was assessed at landmark points (6, 12, and 24 months) and best kidney response.Main Outcomes and MeasuresCumulative incidence of progression to KRT and OS.ResultsSeven-hundred and thirty-two patients (335 women [45.8%]) were included, with a median (IQR) age of 63 (55-69) years. The median (IQR) baseline 24-hour proteinuria and estimated glomerular filtration rate was 5.3 (2.8-8.5) g per 24 hours and 72 (48-92) mL/min/1.73m2, respectively. In a competing-risk analysis, the 5-year cumulative incidence rates of progression to KRT decreased with deeper kidney responses as early as 6 months from therapy initiation (11%, 12%, 2.1%, and 0% for kidNR, kidPR, kidVGPR, and kidCR, respectively; P = .002) and were maintained at 12 months and 24 months and best kidney response. Patients able to achieve kidCR/kidVGPR by 24 months and at best response had significantly better OS compared with kidPR/kidNR. Kidney progression, defined as a 25% or greater decrease in estimated glomerular filtration rate, was associated with cumulative incidence of progression to KRT and OS.Conclusions and RelevanceThe results of this cohort study suggest that graded kidney response criteria offers clinically and prognostically meaningful information for treating patients with kidney AL amyloidosis. The response criteria potentially inform kidney survival based on the depth of reduction in 24-hour proteinuria levels and demonstrate an OS advantage for those able to achieve kidCR/kidVGPR compared with kidPR/kidNR. Taken together, achievement of at least kidVGPR by 12 months is needed to ultimately improve kidney and patient survival.
Navigating Progress: 8-Year Single-Center Experience With Minimally Invasive Proctectomy and IPAA
Violante, Tommaso , Ferrari, Davide , Mathis, Kellie L. , Behm, Kevin T. , Shawki, Sherief , Dozois, Eric J. , Cima, Robert R. , Larson, David W. , Violante, Tommaso , Larson, David W , Cima, Robert , Ferrari, Davide

Diseases of the Colon & Rectum | August 1, 2024 | Volume: 67 | Issue: 11 | Pages: 1437-1442

10.1097/dcr.0000000000003465 | PMID 39087676 Get It

BACKGROUND: IPAA has become the criterion standard for treating ulcerative colitis, familial adenomatous polyposis, and selected cases of Crohn’s colitis. Robotic surgery promises improved postoperative outcomes and decreased length of stay. However, few studies have evaluated the benefits of robotic IPAA compared to laparoscopy. OBJECTIVE: To compare short-term 30-day postoperative outcomes of robotic versus laparoscopic proctectomy with IPAA and diverting loop ileostomy. DESIGN: Retrospective observational study from a single, high-volume center. SETTINGS: Mayo Clinic, Rochester, Minnesota (tertiary referral center for IBD). PATIENTS: All adult patients undergoing minimally invasive proctectomy with IPAA and diverting loop ileostomy between January 2015 and April 2023. MAIN OUTCOME MEASURES: Thirty-day complications, hospital length of stay, estimated blood loss, conversion rate, 30-day readmission, and 30-day reoperation. RESULTS: Two hundred seventeen patients were included in the study; 107 underwent robotic proctectomy with IPAA and diverting loop ileostomy, whereas 110 had laparoscopic proctectomy with IPAA and diverting loop ileostomy. Operating time was significantly longer in the robotic group (263 ± 38 vs 228 ± 75 minutes, p < 0.0001). The robotic group also had lower estimated blood loss (81.5 ± 77.7 vs 126.8 ± 111.0 mL, p = 0.0006) as well as fewer conversions (0% vs 8.2%, p = 0.003). Patients in the robotic group received more intraoperative fluids (3099 ± 1140 vs 2472 ± 996 mL, p = 0.0001). However, there was no difference in length of stay, 30-day morbidity, 30-day readmission, 30-day reoperation, rate of diverting loop ileostomy closure at 3 months, and surgical IPAA complication rate after ileostomy closure. LIMITATIONS: Retrospective design, single-center study, potential bias because of the novelty of the robotic approach, and lack of long-term and quality-of-life outcomes. CONCLUSIONS: Robotic proctectomy with IPAA and diverting loop ileostomy may offer advantages in terms of estimated blood loss and conversion rate while maintaining the benefits of minimally invasive surgery. Further research is needed to evaluate long-term outcomes. See Video Abstract. NAVEGANDO EL PROGRESO: EXPERIENCIA DE OCHO AÑOS EN UN SOLO CENTRO CON PROCTECTOMÍA MÍNIMAMENTE INVASIVA Y ANASTOMOSIS ANAL-BOLSA ILEAL ANTECEDENTES: La anastomosis anal-bolsa ileal (IPAA) se ha convertido en el estándar de oro para el tratamiento de la colitis ulcerosa, la poliposis adenomatosa familiar y casos seleccionados de colitis de Crohn. La cirugía robótica promete mejores resultados posoperatorios y una menor duración de la estancia hospitalaria. Sin embargo, pocos estudios han evaluado los beneficios de la IPAA robótica en comparación con la laparoscopia. OBJETIVO: Comparar los resultados postoperatorios a corto plazo a 30 días de la proctectomía robótica versus laparoscópica con IPAA e ileostomía en asa de derivación. DISEÑO: Estudio observacional retrospectivo de un único centro de gran volumen. AJUSTES: Mayo Clinic, Rochester, Minnesota (centro terciario de referencia para EII). PACIENTES: Todos los pacientes adultos sometidos a proctectomía mínimamente invasiva con IPAA y DLI entre Enero de 2015 y Abril de 2023. PRINCIPALES MEDIDAS DE RESULTADOS: Complicaciones a los 30 días, duración de la estancia hospitalaria, pérdida de sangre estimada, tasa de conversión, reingreso a los 30 días y reoperación a los 30 días. RESULTADOS: Se incluyeron en el estudio 217 pacientes; 107 se sometieron a proctectomía robótica con IPAA y DLI, mientras que 110 se sometieron a proctectomía laparoscópica con IPAA y DLI. El tiempo operatorio fue significativamente mayor en el grupo robótico (263 ± 38 minutos versus 228 ± 75 minutos, p < 0,0001); la pérdida de sangre estimada (EBL) fue menor en el grupo robótico (81,5 ± 77,7 ml versus 126,8 ± 111,0 ml, p = 0,0006), así como el número de conversiones (0% versus 8,2%, p = 0,003). Los pacientes del grupo robótico recibieron más líquidos intraoperatorios (3099 ± 1140 ml versus 2472 ± 996 ml, p = 0,0001). Sin embargo, no hubo diferencias en la duración de la estancia hospitalaria, la morbilidad a los 30 días, el reingreso a los 30 días, la reoperación a los 30 días, la tasa de cierre del DLI a los tres meses y la tasa de complicaciones quirúrgicas de la IPAA después del cierre de la ileostomía. LIMITACIONES: Diseño retrospectivo, estudio unicéntrico, posible sesgo debido a la novedad del enfoque robótico, falta de resultados a largo plazo y de calidad de vida. CONCLUSIONES: La proctectomía robótica con IPAA y DLI puede ofrecer ventajas en términos de EBL y tasa de conversión, manteniendo al mismo tiempo los beneficios de la cirugía mínimamente invasiva. Se necesita más investigación para evaluar los resultados a largo plazo. (Traducción—Dr. Yesenia Rojas-Khalil)
Anterior Cruciate Ligament Tears in Soccer Players
Tagliero, Adam J. , Miller, Mark D., Tagliero, Adam

Sports Medicine and Arthroscopy Review | August 1, 2024 | Volume: 32 | Issue: 3 | Pages: 138-145

10.1097/jsa.0000000000000391 | PMID 39087703 Get It

Anterior cruciate ligament (ACL) injuries to soccer players present unique challenges in sports medicine, given the sport’s global prevalence and intricate injury dynamics. These injuries, especially in the youth and female demographic, have become a substantial concern in sports medicine. This review explores the epidemiology, mechanism of injury, diagnostic procedures, treatment modalities, and rehabilitation strategies related to ACL tears within the soccer community. Progress in diagnostics, treatments, and rehabilitation underscores the importance of evidence-based approaches. As soccer continues its ascent in popularity, addressing the specific risks and nuances of ACL injuries in this context remains of paramount significance.
Feasibility of intentional bioprosthetic valve fracture in the tricuspid position
Hagel, Jonathon A. , Qureshi, Athar M. , Tanase, Daniel , Eicken, Andreas , Zampi, Jeffrey D. , Cabalka, Allison K. , Anderson, Jason H. , Shahanavaz, Shabana , Qureshi, Athar M , Tanase, Daniel , Zampi, Jeffrey D , Cabalka, Allison , Anderson, Jason , Lin, C. Huie

Catheterization and Cardiovascular Interventions | August 1, 2024 | Volume: 104 | Issue: 3 | Pages: 523-530

10.1002/ccd.31168 | PMID 39087728 Get It

AbstractBackgroundTranscatheter tricuspid valve‐in‐valve (ViV) replacement has yielded good hemodynamic outcomes in the treatment of dysfunctional bioprosthetic valves (BPVs). Intentional fracture of certain rigid BPV frames, if feasible, allows a larger implanted valve when compared with implant into an unfractured BPV. There remains limited data on the feasibility of tricuspid valve frame fracture.AimsEvaluate the feasibility of transcatheter tricuspid ViV replacement with fracture of the underlying BPV ring.MethodsAn international multicenter registry of tricuspid ViV replacement with intentional tricuspid valve frame fracture was created. Demographic data along with procedural characteristics, outcomes, and follow‐up data were collected. Comparison was made to the pre‐ and post‐ViV replacement with fracture of the tricuspid valve frame conditions.ResultsTen patients from six centers were included with a median age and weight of 29 years and 67.3 kg respectively. Tricuspid valve frame fracture was performed using a median balloon diameter 3 mm (IQR 3–5) larger than the true inner diameter (ID). The final ID was a mean of 1.5 mm (95% CI: 0.35, 2.64: p < 0.05), and median 1.1 mm (0.5, 2.1) larger than the reported true ID of the surgical BPV after ViV replacement. The mean tricuspid inflow gradient by echocardiogram decreased by 6.65 mmHg (95% CI: 4.14, 9.15: p < 0.001). All procedures were without complication, specifically there was no heart block, pericardial effusion, or right coronary disruption.ConclusionIntentional tricuspid valve frame fracture with tricuspid ViV replacement is feasible and can increase the valve orifice potentially reducing the risk of ViV patient prosthesis mismatch and is not associated with significant complications.
Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural Invasion
Wang, Xiaofei , Damman, Bryce , Wigle, Dennis A. , Port, Jeffrey L., Ashrafi, Ahmad S., Liberman, Moïshe , Landreneau, Rodney J., Yasufuku, Kazuhiro, Yang, Stephen C. , Mitchell, John D. , Keenan, Robert J. , Miller, Daniel P. , Kozono, David , Mentlick, Jennifer, Vokes, Everett E., Stinchcombe, Thomas E. , Wigle, Dennis, Kozono, David E , Altorki, Nasser Khaled , Jones, David R. , Conti, Massimo , BAUER, THOMAS L , Miller, Daniel, Vokes, Everett E.

JAMA Oncology | August 1, 2024 | Volume: 10 | Issue: 9 | Pages: 1179

10.1001/jamaoncol.2024.2491 | PMID 39088196 Get It

Importance The randomized clinical trial Cancer and Leukemia Group B (CALGB) 140503 showed that for patients with clinically staged T1N0 non–small cell lung cancer (NSCLC; ≤2 cm), sublobar resections were associated with similar oncological outcomes to those after lobar resection. The association of the extent of parenchymal resection with recurrence and survival in patients with tumors pathologically upstaged to T2 based on visceral pleural invasion (VPI) is controversial. Objective To determine survival and recurrence rates in patients with small peripheral pT2 NSCLC (≤2 cm) that was treated by either lobar or sublobar resection in CALGB 140503. Design, Participants, and Setting CALGB 140503, a randomized multicenter noninferiority trial, included 697 patients with small peripheral NSCLC that was clinically staged as T1N0. Enrollment was from June 2007 through March 2017 at 83 participating institutions, and after a median follow-up of 7 years, the primary outcome of disease-free survival after sublobar resection was noninferior to that after lobar resection. Intervention Lobar or sublobar resection. Main Outcomes and Measures Survival end points were estimated by the Kaplan-Meier estimator. Hazard ratios and 95% CIs were estimated using stratified Cox proportional hazard models. Results Of 679 participants, 390 (57.4%) were female, and the median (range) age was 67.8 (37.8-89.7) years. Among 697 patients randomized, 566 (81.2%) had pT1 tumors (no VPI) and 113 (16.2%) had pT2 tumors (VPI). Five-year disease-free survival was 65.9% (95% CI, 61.9%-70.2%) in patients with pT1 compared with 53.3% (95% CI, 44.3%-64.1%) in patients with pT2 tumors (stratified log-rank: P = .02). Disease recurrence developed in 27.6% of patients with pT1 (locoregional only: 60 [10.8%]; distant only: 81 [14.6%]) and 41.6% of those with pT2 (locoregional only: 17 [15.0%]; distant only: 27 [23.9%]). Five-year recurrence-free survival was 73.1% (95% CI, 69.2%-77.1%) for pT1 tumors and 58.2% (95% CI, 49.2%-68.8%) for pT2 tumors (stratified log-rank: P = .01). There were no intergroup differences in disease-free or recurrence-free survival based on the extent of parenchymal resection. Conclusions and Relevance The results of this secondary analysis suggest that compared with patients with tumors without VPI, patients who had tumors with VPI had worse disease-free and recurrence-free survival and a higher rate of local and distant disease recurrence. These high rates of recurrence were independent of the extent of parenchymal resection, and these data support the inclusion of these patients in adjuvant therapy trials. Trial Registration ClinicalTrials.gov Identifier: NCT0049933
Current concepts and targets for preventing the transition of acute to chronic postsurgical pain
Oweidat, Adeeb , Kalagara, Hari , Sondekoppam, Rakesh V. , Kalagara, Hari , Sondekoppam, Rakesh V

Current Opinion in Anaesthesiology | August 1, 2024 | Volume: 37 | Issue: 5 | Pages: 588-596

10.1097/aco.0000000000001424 | PMID 39087396 Get It

Purpose of review It is estimated that approximately a third of patients undergoing certain surgeries may report some degree of persistent pain postoperatively. Chronic postsurgical pain (CPSP) reduces quality of life, is challenging to treat, and has significant socio-economic impact. Recent findings From an epidemiological perspective, factors that predispose patients to the development of CPSP may be considered in relation to the patient, the procedure or, the care environment. Prevention or management of transition from acute to chronic pain often need a multidisciplinary approach beginning early in the preoperative period and continuing beyond surgical admission. The current concepts regarding the role of central and peripheral nervous systems in chronification of pain may provide targets for future therapies but, the current evidence seems to suggest that a multimodal analgesic approach of preventive analgesia along with a continued follow-up and treatment after hospital discharge may hold the key to identify and manage the transitioning of acute to chronic pain. Summary A comprehensive multidisciplinary approach with prior identification of risk factors, minimizing the surgical insult and a culture of utilizing multimodal analgesia and continued surveillance beyond the period of hospitalization is an important step towards reducing the development of chronic pain. A transitional pain service model may accomplish many of these goals.
Tofacitinib Exposure Does Not Increase Postoperative Complications Among Patients With Ulcerative Colitis Undergoing Total Colectomy: A Retrospective Case–Control Study
Gomaa, Ibrahim A. , Aboelmaaty, Sara , Bhatt, Himani , Vierkant, Robert A. , Shawki, Sherief , Larson, David W. , Behm, Kevin T. , Rumer, Kristen K. , Gomaa, Ibrahim , Vierkant, Robert A , Larson, David W

Diseases of the Colon & Rectum | August 1, 2024 | Volume: 67 | Issue: 11 | Pages: 1443-1449

10.1097/dcr.0000000000003440 | PMID 39087684 Get It

BACKGROUND: Ulcerative colitis, total colectomy, and tofacitinib have all been associated with an increased risk of venous thromboembolism. OBJECTIVE: To determine whether preoperative tofacitinib exposure increases venous thromboembolism or other postoperative complications among patients with ulcerative colitis undergoing subtotal colectomy, total colectomy, or total proctocolectomy. DESIGN: Retrospective, case-controlled study at a single institution. SETTINGS: A tertiary referral center. PATIENTS: Adult patients with ulcerative colitis undergoing subtotal colectomy, total colectomy, or total proctocolectomy after 2018 who were taking tofacitinib within 30 days of surgery (n = 56) were compared to age- and sex-matched patients with ulcerative colitis undergoing the same surgeries but who were not exposed to tofacitinib (n = 56). MAIN OUTCOME MEASURE: The primary outcome was differences in the incidence of venous thromboembolism within 90 days of surgery based on tofacitinib exposure. Secondary outcomes were 90-day postoperative complications. RESULTS: Groups were well matched for age (non-tofacitinib: mean 35.2 years [SD 12.0], tofacitinib: 35.9 [SD 12.1], p = 0.36) and sex (41% women in each group, p = 1.00). Medical characteristics were similar between groups except for biological medication exposure 30 days before surgery (non-tofacitinib: 66%, tofacitinib: 36%, p = 0.004). Surgical characteristics did not differ between groups. Most patients were discharged on extended venous thromboembolism prophylaxis (non-tofacitinib: 80% and tofacitinib: 77%). Adjusted for biological exposure, there were no statistically significant differences in venous thromboembolism (non-tofacitinib exposed: 14%, tofacitinib exposed: 4%, p = 0.09) or other postoperative outcomes. LIMITATION: Retrospective, single institutional study. CONCLUSIONS: Among patients with ulcerative colitis undergoing total colectomy or proctocolectomy, exposure to tofacitinib was not associated with an increased risk of venous thromboembolism or other postoperative complications. See Video Abstract . LA EXPOSICIÓN A TOFACITINIB NO AUMENTA LAS COMPLICACIONES POSOPERATORIAS ENTRE PACIENTES CON COLITIS ULCEROSA SOMETIDOS A COLECTOMÍA TOTAL: UN ESTUDIO RETROSPECTIVO DE CASOS Y CONTROLES ANTECEDENTES: La colitis ulcerosa, la colectomía total y el tofacitinib han sido asociados con un mayor riesgo de tromboembolismo venoso. OBJETIVO: Determinar si la exposición preoperatoria a tofacitinib aumenta la tromboembolia venosa u otras complicaciones posoperatorias entre pacientes con colitis ulcerosa sometidos a colectomía subtotal, colectomía total o proctocolectomía total. DISEÑO: Estudio retrospectivo de casos y controles en una sola institución. AJUSTES: Un centro de referencia terciario. PACIENTES: Los pacientes adultos con colitis ulcerosa sometidos a colectomía subtotal, colectomía total o proctocolectomía total después del año 2018 que se encontraron consumiendo tofacitinib dentro de los 30 días posteriores a la cirugía (n = 56) fueron comparados con pacientes con colitis ulcerosa de la misma edad y sexo sometidos a las mismas cirugías pero que no estuvieron expuestos a tofacitinib (n = 56). MEDIDA DE RESULTADO PRINCIPAL: El resultado primario fueron las diferencias en las incidencias de tromboembolismo venoso dentro de los 90 días posteriores a la cirugía según la exposición a tofacitinib. Los resultados secundarios fueron las complicaciones posoperatorias a los 90 días. RESULTADOS: Los grupos se encontraban bien emparejados por edad (sin tofacitinib: media 35,2 años [DE 12,0], tofacitinib: 35,9 [DE 12,1], p = 0,36) y sexo (41% mujeres en cada grupo, p = 1,00). Las características médicas fueron similares entre los grupos, excepto por la exposición a medicamentos biológicos 30 días antes de la cirugía (sin tofacitinib: 66 %, tofacitinib: 36 %, p = 0,004). Las características quirúrgicas no difirieron entre los grupos. La mayoría de los pacientes fueron dados de alta con profilaxis extendida para tromboembolismo venoso (sin tofacitinib: 80% y tofacitinib: 77%). Ajustado a la exposición biológica, no hubo diferencias estadísticamente significativas en el tromboembolismo venoso (no expuestos a tofacitinib: 14%, expuestos a tofacitinib: 4%, p = 0,09) u otros resultados posoperatorios. LIMITACIÓN: Estudio institucional único, retrospectivo. CONCLUSIÓN: Entre los pacientes con colitis ulcerosa sometidos a colectomía total o proctocolectomía, la exposición a tofacitinib no se asoció con un mayor riesgo de tromboembolismo venoso u otras complicaciones posoperatorias. (Traducción—Dr Osvaldo Gauto )
Baseline Normative and Test–Retest Reliability Data for Sideline Concussion Assessment Measures in Youth
Wethe, Jennifer V. , Bogle, Jamie M. , Howard, Marci, Gould, Amanda Rach, Butterfield, Richard , Buras, Matthew , Adler, Jennifer S. , Talaber, Alexandra , Soma, David , Starling, Amaal J. , Bogle, Jamie, Howard, Marci D, Buras, Matthew R , Adler, Jennifer, Starling, Amaal J , Wethe, Jennifer V , Dodick, David W.

Diagnostics | August 1, 2024 | Volume: 14 | Issue: 15 | Pages: 1661

10.3390/diagnostics14151661 | PMID 39125537 Get It

Tools used for the identification, evaluation, and monitoring of concussion have not been sufficiently studied in youth or real-world settings. Normative and reliability data on sideline concussion assessment measures in the youth athlete population is needed. Pre-season normative data for 515 athletes (93.5% male) aged 5 to 16 on the Standardized Assessment of Concussion (SAC/SAC-Child), modified Balance Errors Scoring System (mBESS), Timed Tandem Gait (TTG), and the King–Devick Test (KDT) are provided. A total of 212 non-injured athletes repeated the measures post-season to assess test–retest reliability. Mean performance on the SAC-C, mBESS, TTG, and KDT tended to improve with age. KDT was the only measure that demonstrated good to excellent stability across age ranges (ICC = 0.758 to 0.941). Concentration was the only SAC/SAC-C subtest to demonstrate moderate test–retest stability (ICC = 0.503 to 0.706). TTG demonstrated moderate to good (ICC = 0.666 to 0.811) reliability. mBESS demonstrated poor to moderate reliability (ICC = −0.309 to 0.651). Commonly used measures of concussion vary regarding test–retest reliability in youth. The data support the use of at least annual sport concussion baseline assessments in the pediatric population to account for the evolution in performance as the child ages. Understanding the variation in the stability and the evolution of baseline performance will enable improved identification of possible injury.